ASH Clinical News August 2017 v3 | Page 47

IN HEMOPHILIA B,
THERE’S ONE THING YOU CAN COUNT ON
INNOVATION FROM NOVO NORDISK
We strive to help improve the lives of people with hemophilia
For 30 years, Novo Nordisk has been a driving force
for people living with rare bleeding disorders. We take
pride in striving for innovative solutions to help improve
patients’ lives. This motivates us to uphold the highest
standards in our product research and development.
This vital research is just the beginning of our
commitment in hemophilia.
Through the B-HERO-S study a in hemophilia B, we
uncovered unmet needs around the impact of
hemophilia on education, employment, activities, and
other aspects of the lives of patients and their families.
a
We will continue our research and connect with
patients and health care professionals to ensure we
understand and respond to the specifi c needs of the
hemophilia B community.
With a rich history, Novo Nordisk remains at the forefront
of discovery. We are poised to continue to develop
innovative solutions that can help improve the lives of
patients with hemophilia in the future.
B-HERO-S = Bridging Hemophilia Experiences, Results and Opportunities into Solutions. A U.S. survey of 449 people.
Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Changing Hemophilia ™ is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2017 Novo Nordisk Printed in the U.S.A. USA17BIO02049b August 2017